|
IT1110460B
(it)
*
|
1977-03-02 |
1985-12-23 |
Ciba Geigy Ag |
Prodotti che favoriscono la crescita delle piante e prodotti che proteggono le piante a base di eteri di ossime e di esteri di ossime loro preparazione e loro impiego
|
|
FR2639942B1
(fr)
*
|
1988-12-02 |
1991-03-29 |
Sanofi Sa |
Ethers oximes de propenone, procede pour leur preparation et compositions pharmaceutiques les contenant
|
|
US5665756A
(en)
*
|
1994-08-03 |
1997-09-09 |
Hoechst Marion Roussel, Inc. |
Aminoalkyloximes useful in the treatment of depression and obsessive compulsive disorders
|
|
US6548084B2
(en)
*
|
1995-07-20 |
2003-04-15 |
Smithkline Beecham Plc |
Controlled release compositions
|
|
EP0759299B1
(en)
*
|
1995-08-16 |
2000-04-26 |
Eli Lilly And Company |
Potentiation of serotonin response
|
|
IN182588B
(es)
|
1998-05-12 |
1999-05-08 |
Sun Pharmaceutical Ind Ltd |
|
|
IE990406A1
(en)
|
1999-05-20 |
2000-12-27 |
Elan Corp Plc |
Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
|
|
IN186677B
(es)
|
1999-11-12 |
2001-10-20 |
Sun Pharmaceutical Ind Ltd |
|
|
US20080021085A1
(en)
*
|
2000-04-13 |
2008-01-24 |
Mayo Foundation For Medical Education And Research |
Method of reducing abeta42 and treating diseases
|
|
AU2001257022B2
(en)
*
|
2000-04-13 |
2005-02-03 |
Mayo Foundation For Medical Education And Research |
Abeta 42 lowering agents
|
|
US7256191B2
(en)
*
|
2000-04-24 |
2007-08-14 |
Aryx Therapeutics |
Materials and methods for the treatment of depression
|
|
AU2001255654B2
(en)
*
|
2000-04-24 |
2005-09-22 |
Aryx Therapeutics |
Materials and methods for the treatment of depression
|
|
WO2003079972A2
(en)
|
2002-02-22 |
2003-10-02 |
New River Parmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
|
MXPA04003358A
(es)
*
|
2001-10-12 |
2004-07-08 |
Serenix Pharmaceuticals Llc |
Antagonistas de vasopresina v1a de ?-lactamilo.
|
|
EP1603548A4
(en)
*
|
2003-02-05 |
2007-10-10 |
Myriad Genetics Inc |
COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
|
|
CA2532207A1
(en)
*
|
2003-07-11 |
2005-07-21 |
Myriad Genetics, Inc. |
Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
|
|
ATE449633T1
(de)
|
2003-09-12 |
2009-12-15 |
Pfizer |
Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
|
|
ES2347152T3
(es)
*
|
2003-11-26 |
2010-10-26 |
Pfizer Products Inc. |
Derivados de aminopirazol como inhibidores de gsk-3.
|
|
PT1691811E
(pt)
|
2003-12-11 |
2014-10-30 |
Sunovion Pharmaceuticals Inc |
Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
|
|
WO2006001877A2
(en)
*
|
2004-04-13 |
2006-01-05 |
Myriad Genetics, Inc. |
Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
|
|
CA2567249A1
(en)
*
|
2004-04-19 |
2006-10-05 |
Jds Pharmaceuticals, Llc |
Lithium combinations, and uses related thereto
|
|
AU2005241023A1
(en)
*
|
2004-04-29 |
2005-11-17 |
Keystone Retaining Wall Systems, Inc. |
Veneers for walls, retaining walls and the like
|
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
|
BRPI0514303A
(pt)
*
|
2004-08-11 |
2008-06-10 |
Myriad Genetics Inc |
composição farmacêutica e método para tratar distúrbios neurodegenerativos
|
|
AU2006227199A1
(en)
|
2005-03-22 |
2006-09-28 |
Azevan Pharmaceuticals, Inc. |
Beta-lactamylalkanoic acids for treating premenstrual disorders
|
|
CA2605554A1
(en)
|
2005-04-22 |
2006-11-02 |
Wyeth |
Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
|
|
EP1871356A1
(en)
*
|
2005-04-22 |
2008-01-02 |
Wyeth a Corporation of the State of Delaware |
Dihydrobenzofuran derivatives and uses thereof
|
|
MX2007013179A
(es)
*
|
2005-04-22 |
2008-01-16 |
Wyeth Corp |
Formas cristalinas de clorhidrato de {[(2r)-7-(diclorofenil)-5- fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina.
|
|
PE20061298A1
(es)
|
2005-04-22 |
2006-12-24 |
Wyeth Corp |
Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c
|
|
NZ565683A
(en)
|
2005-07-08 |
2011-04-29 |
Braincells Inc |
Methods for identifying agents and conditions that modulate neurogenesis in human neural cells
|
|
US20070015832A1
(en)
*
|
2005-07-14 |
2007-01-18 |
Myriad Genetics, Incorporated |
Methods of treating overactive bladder and urinary incontinence
|
|
CN101268068B
(zh)
*
|
2005-07-19 |
2015-12-02 |
阿泽范药品公司 |
β-内酰胺基苯丙氨酸、半胱氨酸和丝氨酸血管加压素拮抗剂
|
|
US20070042034A1
(en)
*
|
2005-07-22 |
2007-02-22 |
Myriad Genetics, Incorporated |
High drug load formulations and dosage forms
|
|
EP1940389A2
(en)
|
2005-10-21 |
2008-07-09 |
Braincells, Inc. |
Modulation of neurogenesis by pde inhibition
|
|
US20070112017A1
(en)
|
2005-10-31 |
2007-05-17 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
|
FR2912057B1
(fr)
*
|
2007-02-07 |
2009-04-17 |
Sanofi Aventis Sa |
Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
|
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
US20070225279A1
(en)
*
|
2006-03-24 |
2007-09-27 |
Wyeth |
Therapeutic combinations for the treatment of depression
|
|
JP4615470B2
(ja)
*
|
2006-03-29 |
2011-01-19 |
卓郎 簑和田 |
大脳の認知力を用いた疾患治療・予防の方法および医薬
|
|
MX2008014320A
(es)
|
2006-05-09 |
2009-03-25 |
Braincells Inc |
Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
|
|
EP2021000A2
(en)
|
2006-05-09 |
2009-02-11 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
|
US7858611B2
(en)
*
|
2006-05-09 |
2010-12-28 |
Braincells Inc. |
Neurogenesis by modulating angiotensin
|
|
US20080033045A1
(en)
*
|
2006-07-07 |
2008-02-07 |
Myriad Genetics, Incorporated |
Treatment of psychiatric disorders
|
|
TW200817003A
(en)
*
|
2006-07-31 |
2008-04-16 |
Sanofi Aventis |
Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
|
|
EP2068872A1
(en)
|
2006-09-08 |
2009-06-17 |
Braincells, Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
|
US20100016274A1
(en)
*
|
2006-09-14 |
2010-01-21 |
Koppel Gary A |
Beta-lactam cannabinoid receptor modulators
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
WO2008083204A2
(en)
*
|
2006-12-28 |
2008-07-10 |
Braincells, Inc. |
Modulation of neurogenesis by melatoninergic ligands
|
|
CA2675132A1
(en)
*
|
2007-01-11 |
2008-07-17 |
Braincells, Inc. |
Modulation of neurogenesis with use of modafinil
|
|
WO2009128058A1
(en)
|
2008-04-18 |
2009-10-22 |
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al |
Psycho-pharmaceuticals
|
|
WO2010021681A2
(en)
*
|
2008-08-18 |
2010-02-25 |
Combinatorx (Singapore) Pte. Ltd. |
Compositions and methods for treatment of viral diseases
|
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
KR101859400B1
(ko)
|
2009-10-23 |
2018-05-18 |
얀센 파마슈티카 엔.브이. |
오렉신 수용체 조절제로서의 이치환된 옥타하이드로피롤로［3,4-ｃ］피롤
|
|
EP2509596B1
(en)
|
2009-12-08 |
2019-08-28 |
Case Western Reserve University |
Gamma aminoacids for treating ocular disorders
|
|
WO2012003436A1
(en)
|
2010-07-01 |
2012-01-05 |
Azevan Pharmaceuticals, Inc. |
Methods for treating post traumatic stress disorder
|
|
BR112013023810A2
(pt)
|
2011-03-17 |
2016-12-13 |
Lupin Ltd |
composições farmacêuticas de liberação controlada de inibidores seletivos da recaptação de serotonina
|
|
KR101427221B1
(ko)
*
|
2012-08-29 |
2014-08-13 |
주식회사 에스텍파마 |
플루복사민 자유 염기의 정제방법 및 이를 이용한 고순도 플루복사민 말레이트의 제조방법
|
|
WO2014178064A2
(en)
*
|
2013-04-03 |
2014-11-06 |
Zcl Chemicals Limited |
"an improved process for the preparation of fluvoxamine maleate"
|
|
DK3104847T3
(da)
|
2014-02-07 |
2021-02-01 |
Tamogatott Kutatocsoportok Irodaja |
Hidtil ukendt anvendelse af sigma-1-receptoragonistforbindelser
|
|
SG11201608064WA
(en)
|
2014-03-28 |
2016-10-28 |
Azevan Pharmaceuticals Inc |
Compositions and methods for treating neurodegenerative diseases
|
|
LT3426251T
(lt)
|
2016-03-10 |
2022-06-27 |
Janssen Pharmaceutica Nv |
Depresijos gydymo būdai, panaudojant oreksino-2 receptoriaus antagonistus
|
|
CA3044746A1
(en)
|
2016-11-24 |
2018-05-31 |
Sigmadrugs Kutato Korlatolt Felelossegu Tarsasag |
Compositions for organ preservation
|
|
US11628160B2
(en)
|
2017-09-15 |
2023-04-18 |
Azevan Pharmaceuticals, Inc. |
Compositions and methods for treating brain injury
|